(1). AIDS.gov, Global Statistics. http://www.aids.gov/hiv-aids-basics/hiv-aids-101/global-statistics/
(2). Tie, Y., et al, 2012. Critical Differences in HIV-1 and HIV-2 Protease Specificity for Clinical Inhibitors. Protein Science 21: 339-350.
(3). Shen, C-H., et al, 2010. Amprenavir Complexes with HIV-1 Protease and its Drug-Resistant Mutants Altering Hydrophobic Clusters. FEBS Journal 277: 3699-3714.
(4). Chou, K-C. 1996. Prediction of Human Immunodeficiency Virus Protease Cleavage Sites in Proteins. Analytical Biochemistry 233: 1-14.
(5). Protein identification and analysis tools on the ExPASy server. Gasteiger, E. et. al. In J. M. Walker (Ed.)
(6). Brik, A., Wong, C-H., 2003. HIV-1 Protease: Mechanism and Drug Discovery. Organic & Biomolecular Chemistry 1: 5-14.
(7). Saskova, K., et al, 2009. Molecular Characterization of Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir. Journal of Virology 83: 8810-8818.
(8). NCBI BLAST. http://www.ncbi.nlm.nih.gov/blast/Blast.cgi?CMD=Web&PAGE _TYPE=BlastHome.
(9). Dali server: conservation mapping in 3D. Nucl. Acids Res. 38, W545-549. Holm L, Rosenström, P. 2010.
(10). Gustchina, A., Weber, I., 1991. Comparative Analysis of the Sequences and Structures of HIV-1 and HIV-2 Proteases. Proteins: Structure, Function, and Genetics 10: 325-339.
(11).
Kovalesvsky, A., et al, 2008. Structural Evidence for Effectiveness of
Darunavir and Two Related Antiviral Inhibitors against HIV-2 Protease. Journal of Molecular Biology 384: 178-192.